Sorrento
Therapeutics focuses on the research and development of therapeutic products for the treatment of cancer, inflammation and autoimmune diseases... Read moreSorrento
Therapeutics focuses on the research and development of therapeutic products for the treatment of cancer, inflammation and autoimmune diseases... Read more
News
Mar 28, 2025
Bloomberg Law
Sorrento: Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
May 10, 2024
Marketscreener
Sorrento: Ninth Circuit Rules That Biopharmaceutical Company's Announcement Of COVID-19 "Cure" Did Not Violate Securities Laws
Mar 25, 2024
Bloomberg Law
Sorrento: Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Mar 12, 2024
BusinessDen
Sorrento: Monument distillery closes, files for bankruptcy
Mar 06, 2024
Pharamceutical Technology
Sorrento: Sorrento Therapeutics files patent for stable oral liquid pharmaceutical composition of celecoxib for pain relief
Feb 27, 2024
The Business Journals: Philadelphia
Sorrento: Virpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex Pharmaceuticals
Dec 19, 2023
Bloomberg Law
Sorrento: Sorrento Shareholders Lose Bid to Probe Judge Romance Knowledge
Nov 14, 2023
Bloomberg Law
Sorrento: Sorrento Moves to Block Calls for Judge Relationship Information
Sep 22, 2023
MarketScreener
Sorrento: Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Sep 12, 2023
Benzinga
Sorrento: Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Sorrento Competitors
1
2
3
4
5
6
7
8
9
10